Our purpose is to accelerate the development of cancer medicines and treatments
Talk to our team
We’d like to hear from you
Read the latest news from Ellipses Pharma
Ellipses Pharma on our unique approach to developing cancer medicines faster
Ellipses Pharma on our unique approach to developing cancer medicines faster Hear from our Chairman, Professor Sir Chris Evans, our CEO, Dr Rajan Jethwa and our Global Head of Drug Development, Professor Tobi Arkenau alongside other industry experts and get a look inside Ellipses to discover how our unique approach develops cancer medicines faster. This [...]
Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA
Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours. Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today that [...]
ODD granted by FDA
Ellipses EP0031 granted Orphan Drug Designation from the US Food and Drug Administration EP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug [...]
